Unbound MEDLINE

A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2. Dermatitis : contact, atopic, occupational, drug : official journal of the American Contact Dermatitis Society, North American Contact Dermatitis Group [Dermatitis] Journal article

 
TitleA mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2.
Author(s)Bremmer M, Deng A, Gaspari AA 
InstitutionDepartment of Dermatology, University of Maryland, Baltimore, MD, USA.
SourceDermatitis 2009 Oct; 20(5):243-56.
AbstractBiologic therapies are an efficacious new method of controlling a number of chronic conditions. Data regarding these medications continues to emerge, giving clinicians a greater understanding of their side effects profiles. The biologic agents used in dermatology, particularly the tumor necrosis factor-alpha inhibitors, have a number of varied dermatologic side effects. In this two-part article, we perform a review of literature regarding cutaneous side effects of infliximab, etanercept, adalimumab, rituximab, efalizumab, and alefacept. In this second part, we discuss injection site reactions, infusion reactions, vasculitis, drug-induced lupus erythematosus, psoriasiform lesions, rebound phenomenon, eczema, atopic dermatitis, and hypersensitivity reactions.
Languageeng
Pub Type(s)Journal Article
PubMed ID19807998
  
Advertise on this site.